Evaluation of Mesenchymal stem cell therapy effects on the cellular immune response in refractory rheumatoid arthritis patients
Phase 1
- Conditions
- Rheumatoid arthritis.Diseases of the musculoskeletal system and connective tissue
- Registration Number
- IRCT2015102824760N1
- Lead Sponsor
- Research Chancellor, Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 21
Inclusion Criteria
Resistant RA patients to non-biological DMARDs
Treated RA patients by non-biological drugs
Treated RA patients by Prednisolone, Hydroxychloroquine, Sulfasalazine and Methotrexate
Patients aged between 35-60 years
Refractory RA patients with no other rheumatologic disorders and inflammatory diseases
Exclusion Criteria
Non-resistant RA patients to non-biological DMARDs
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method